These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 37778468)
1. Small EV-based delivery of CpG ODNs for melanoma postsurgical immunotherapy. Lu Y; Ye H; Zhao J; Wang K; Fan X; Lu Q; Cao L; Wan B; Liu F; Sun F; Chen X; He Z; Liu H; Sun J J Control Release; 2023 Nov; 363():484-495. PubMed ID: 37778468 [TBL] [Abstract][Full Text] [Related]
2. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence. Li M; Guo R; Wei J; Deng M; Li J; Tao Y; Li M; He Q Acta Biomater; 2021 Dec; 136():546-557. PubMed ID: 34536603 [TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides. Yu C; An M; Li M; Liu H Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452 [TBL] [Abstract][Full Text] [Related]
4. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352 [TBL] [Abstract][Full Text] [Related]
5. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Heo MB; Kim SY; Yun WS; Lim YT Int J Nanomedicine; 2015; 10():5981-92. PubMed ID: 26451105 [TBL] [Abstract][Full Text] [Related]
6. Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors. Cerkovnik P; Jezersek Novakovic B; Stegel V; Novakovic S Innate Immun; 2009 Oct; 15(5):313-21. PubMed ID: 19723833 [TBL] [Abstract][Full Text] [Related]
7. Programmable Delivery of Immune Adjuvant to Tumor-Infiltrating Dendritic Cells for Cancer Immunotherapy. Liu J; Li HJ; Luo YL; Chen YF; Fan YN; Du JZ; Wang J Nano Lett; 2020 Jul; 20(7):4882-4889. PubMed ID: 32551705 [TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. Jérôme V; Graser A; Müller R; Kontermann RE; Konur A J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372 [TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558 [TBL] [Abstract][Full Text] [Related]
11. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989 [TBL] [Abstract][Full Text] [Related]
12. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes. Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350 [TBL] [Abstract][Full Text] [Related]
13. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352 [TBL] [Abstract][Full Text] [Related]
14. Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant. Cui G; Sun Y; Qu L; Shen C; Sun Y; Meng F; Zheng Y; Zhong Z Adv Healthc Mater; 2024 Jul; 13(17):e2303690. PubMed ID: 38458152 [TBL] [Abstract][Full Text] [Related]